Clinical Trials Directory

Trials / Completed

CompletedNCT04013386

Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting

Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting After Laparoscopic Sleeve Surgery: a Randomized Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
90 (actual)
Sponsor
Ain Shams University · Academic / Other
Sex
All
Age
25 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Laparoscopic sleeve gastrectomy (LSG) is an emerging treatment modality among the various types of surgical approach to obesity (1). The incidence of PONV in obese patients undergoing bariatric surgery, who did not receive antiemetic prophylaxis, is high at nearly 70-80 % (2,3). Postoperatively, bariatric patients appear to suffer from nausea and vomiting more frequently than normal weight or obese patients.

Detailed description

Currently, available interventions for PONV prophylaxis, especially as monotherapy, lack universal efficacy. Use of combination therapies with different pharmacological basis is likely to bring down rates of PONV. (6) Intravenous dexamethasone (8-10mg) reduces the incidence of PONV, minimizing activity of phospholipase A2 and blocking the expression of cyclooxygenase (COX)2 mRNA that reduce production of prostaglandin and control the release of endorphins. Aprepitant has demonstrated powerful additive effects when combined with dexamethasone and a 5-HT3 to prevent both acute and delayed chemotherapy-induced nausea and vomiting (CINV), and in the prevention of postoperative nausea and vomiting (PONV) The use of mirtazapine in the management of nausea and vomiting has been reported for both treatment and premedication

Conditions

Interventions

TypeNameDescription
DRUGAprepitant and DexamethasoneAprepitant capsule 80 mg and Dexamethasone 8 mg IVI
DRUGMirtazapine and DexamethasoneMirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
DRUGDexamethasoneDexamethasone 8 mg IVI

Timeline

Start date
2019-07-15
Primary completion
2019-12-31
Completion
2019-12-31
First posted
2019-07-09
Last updated
2020-01-03

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04013386. Inclusion in this directory is not an endorsement.